Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

  • Jun Guo1Email author,
  • Yiran Huang2,
  • Xu Zhang3,
  • Fangjian Zhou4,
  • Yinghao Sun5,
  • Shukui Qin6,
  • Zhangqun Ye7,
  • Hui Wang8,
  • Annette Jappe9,
  • Patrick Straub10,
  • Nicoletta Pirotta11 and
  • Sven Gogov12
BMC Cancer201313:136

DOI: 10.1186/1471-2407-13-136

Received: 18 September 2012

Accepted: 11 March 2013

Published: 21 March 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
18 Sep 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
26 Sep 2012 Author responded Author comments - Jun Guo
Resubmission - Version 3
26 Sep 2012 Submitted Manuscript version 3
26 Nov 2012 Reviewed Reviewer Report - Brian Rini
10 Dec 2012 Reviewed Reviewer Report - Ronald Bukowski
18 Jan 2013 Author responded Author comments - Jun Guo
Resubmission - Version 4
18 Jan 2013 Submitted Manuscript version 4
Publishing
11 Mar 2013 Editorially accepted
21 Mar 2013 Article published 10.1186/1471-2407-13-136

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article.. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Peking University Cancer Hospital and Institute
(2)
Shanghai Renji Hospital
(3)
The General Hospital of PLA
(4)
Sun Yat-sen University Cancer Center
(5)
Shanghai Changhai Hospital
(6)
Nanjing Bayi Hospital
(7)
Wuhan Tongji Hospital
(8)
Beijing Novartis Pharma Company, Ltd.
(9)
Novartis Pharma AG
(10)
Novartis Pharma AG
(11)
Novartis Pharma AG
(12)
Novartis Pharma AG

Advertisement